Orchestra Biomed Holdings, Inc. (OBIO)
NASDAQ:OBIO
Want to see OBIO full AI Analyst Report?
OBIO Stock Chart & Stats
$4.58
-$0.06(-1.07%)
At close: 4:00 PM EST
$4.58
-$0.06(-1.07%)
Day’s Range― - ―
52-Week Range$2.20 - $5.42
Previous CloseN/A
Volume15.92K
Average Volume (3M)258.58K
Market Cap
$238.92M
Enterprise Value$237.01M
Total Cash (Recent Filing)$94.40M
Total Debt (Recent Filing)$33.63M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Aug 18, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding59,880,714
10 Day Avg. Volume266,593
30 Day Avg. Volume258,580
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.51
Price to Sales (P/S)4.76
P/FCF Ratio-3.22
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue7.24
Enterprise Value/Gross Profit7.30
Enterprise Value/Ebitda-4.50
Forecast
1Y Price Target
$11.40Price Target Upside148.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$545.43K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Asset BaseThe company's very low debt (debt-to-equity ~0.04) and sizable asset base provide durable financial flexibility to fund clinical programs or absorb near-term setbacks. This balance-sheet strength reduces immediate refinancing pressure and supports R&D investments while management pursues commercialization paths.
High Gross MarginsExtremely high gross margins imply favorable unit economics for the company's device offerings once sold at scale. If fixed operating costs are progressively absorbed as revenue grows, these margins can materially improve operating leverage and support sustainable profitability over the medium term.
Device-Focused Model & PartnershipsA clear strategic focus on device-based cardiovascular therapies combined with an expressed partnering/commercialization approach can accelerate market access and limit commercialization capital needs. Leveraging larger partners is a structurally durable route to scale sales, regulatory navigation, and distribution.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flows of roughly -$54M to -$55M TTM indicate the company is consuming significant cash to fund operations and development. This persistent burn creates ongoing financing risk, increasing likelihood of dilution or the need for partner/licensing deals to fund programs.
Deep, Persistent LossesLarge recurring net losses and a severely negative ROE reflect structural unprofitability and shareholder value dilution. Converting the business to sustained profitability requires substantial margin improvement or revenue scale; absent that, management faces material operational and capital-allocation challenges.
Volatile / Declining Revenue TrendsSharp year-over-year revenue volatility and a massive decline versus the prior period undermine predictability of future cash flows and program economics. This inconsistency complicates planning, investor confidence, and the timing of break-even attainment, raising execution and financing risk.
Orchestra BioMed Holdings News
OBIO FAQ
What was Orchestra Biomed Holdings, Inc.’s price range in the past 12 months?
Orchestra Biomed Holdings, Inc. lowest stock price was $2.20 and its highest was $5.42 in the past 12 months.
What is Orchestra Biomed Holdings, Inc.’s market cap?
Orchestra Biomed Holdings, Inc.’s market cap is $238.92M.
When is Orchestra Biomed Holdings, Inc.’s upcoming earnings report date?
Orchestra Biomed Holdings, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 58 days.
How were Orchestra Biomed Holdings, Inc.’s earnings last quarter?
Orchestra Biomed Holdings, Inc. released its earnings results on May 12, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.1.
Is Orchestra Biomed Holdings, Inc. overvalued?
According to Wall Street analysts Orchestra Biomed Holdings, Inc.’s price is currently Undervalued.
Does Orchestra Biomed Holdings, Inc. pay dividends?
Orchestra Biomed Holdings, Inc. does not currently pay dividends.
What is Orchestra Biomed Holdings, Inc.’s EPS estimate?
Orchestra Biomed Holdings, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Orchestra Biomed Holdings, Inc. have?
Orchestra Biomed Holdings, Inc. has 59,880,714 shares outstanding.
What happened to Orchestra Biomed Holdings, Inc.’s price movement after its last earnings report?
Orchestra Biomed Holdings, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Orchestra Biomed Holdings, Inc.?
Currently, no hedge funds are holding shares in OBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orchestra BioMed Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.40 (148.91% Upside)
$11.40 (148.91% Upside)
Hedge Fund Trend
Decreased
By 89.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $158.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.44%
12-Months-Change
Fundamentals
Return on Equity
-137.99%
Trailing 12-Months
Asset Growth
70.46%
Trailing 12-Months
Company Description
Orchestra Biomed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
OBIO Stock 12 Month Forecast
Average Price Target
$11.40
▲(148.91% Upside)
Technical Analysis
Cardiff Oncology
―
Greenwich LifeSciences
―
Climb Bio
―
Cognition Therapeutics
―
Pyxis Oncology
―
Ownership Overview
30.95% Insiders
4.90% Mutual Funds
28.15% Other Institutional Investors
31.33% Public Companies and
Individual Investors